Janus Henderson Group PLC Buys 13,920 Shares of Haemonetics Co. (NYSE:HAE)

Janus Henderson Group PLC raised its position in Haemonetics Co. (NYSE:HAE - Free Report) by 29.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,436 shares of the medical instruments supplier's stock after acquiring an additional 13,920 shares during the quarter. Janus Henderson Group PLC owned approximately 0.12% of Haemonetics worth $4,720,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Boston Trust Walden Corp boosted its stake in shares of Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Haemonetics during the 4th quarter valued at about $319,000. Pacer Advisors Inc. boosted its stake in shares of Haemonetics by 36.1% during the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock valued at $789,000 after purchasing an additional 2,680 shares in the last quarter. Norges Bank bought a new stake in shares of Haemonetics during the 4th quarter valued at about $32,803,000. Finally, Voya Investment Management LLC boosted its stake in shares of Haemonetics by 820.5% during the 4th quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after purchasing an additional 282,521 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. JMP Securities reaffirmed a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research note on Tuesday. Raymond James reaffirmed a "strong-buy" rating and set a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Needham & Company LLC cut their target price on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and cut their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $97.89.

Haemonetics Stock Down 0.1%

NYSE:HAE traded down $0.06 during mid-day trading on Friday, hitting $66.10. 356,407 shares of the company's stock were exchanged, compared to its average volume of 683,601. Haemonetics Co. has a one year low of $55.30 and a one year high of $94.99. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The business has a fifty day moving average price of $63.13 and a 200 day moving average price of $70.99. The company has a market cap of $3.32 billion, a PE ratio of 26.02, a P/E/G ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.22 by $0.02. The business had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics's quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.90 earnings per share. Equities analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.